SCHEMBL4174366

SCHEMBL4174366

CC(C)n1cc(CN2CCCC2)c2cc(NC(=O)Oc3ccccc3)ccc21

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NPY5R Q15761 3/20 0.46
▸ ALDH1A1 P00352 5/20 0.44
▸ MAPT P10636 3/20 0.43
▸ GAA P10253 4/20 0.42
▸ KMT2A Q03164 2/20 0.42
▸ MEN1 O00255 1/20 0.42
▸ LMNA P02545 1/20 0.42
▸ TP53 P04637 1/20 0.42
▸ PLA2G4A P47712 1/20 0.41
▸ SSTR5 P35346 1/20 0.41
▸ NPSR1 Q6W5P4 1/20 0.41
▸ TRPV1 Q8NER1 2/20 0.41
▸ HPGD P15428 1/20 0.40
▸ CYP1A2 P05177 1/20 0.40
▸ BRD4 O60885 1/20 0.40
▸ RECQL P46063 1/20 0.40
▸ SMN1; SMN2 Q16637 1/20 0.40
▸ POLB P06746 1/20 0.40
▸ KDM4E B2RXH2 1/20 0.40
▸ USP2 O75604 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3386016 0.80 CACNB4 (0.46) ALDH1A1GAAHPGDCYP1A2POLB
SCHEMBL4178385 0.74 F2R (0.50) ALDH1A1MAPTGAAHPGDCYP1A2
SCHEMBL4316805 0.74 GAA (0.46) ALDH1A1MAPTGAALMNANPSR1
SCHEMBL2776874 0.74 ABL1 (0.53) ALDH1A1MAPTKMT2AMEN1
SCHEMBL6753270 0.72 PTGDR2 (0.47) NPY5RALDH1A1MAPTGAAKMT2A
SCHEMBL29959139 0.72 ABL1 (0.53) ALDH1A1MAPTKMT2AMEN1
SCHEMBL3386295 0.71 ALDH1A1 (0.52) ALDH1A1MAPTGAAKMT2AMEN1
SCHEMBL16629103 0.69 POLB (0.55) ALDH1A1MAPTKMT2AMEN1TP53
SCHEMBL25802168 0.69 GAA (0.57) ALDH1A1MAPTGAALMNANPSR1
SCHEMBL25802440 0.69 GAA (0.57) ALDH1A1MAPTGAAKMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090012263-A1 Process for Production of (1,3-Disubstituted Indolyl)-Urea Derivatives, Intermediates Therefor, and Process for Production of the Intermediates KOWA COMPANY, LTD. (JP) 2009-01-08 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090012263-A1 Process for Production of (1,3-Disubstituted Indolyl)-Urea Derivatives, Intermediates Therefor, and Process for Production of the Intermediates WEE1, WASF2, IDO1 NPY5R 646/4885ALDH1A1 2230/4885MAPT 1939/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback